Glaukos Corporation Stock News

An analyst downgraded the healthcare stock.

Glaukos (NYSE:GKOS) shares are trading lower after Wells Fargo downgraded the stock from Equal-Weight to Underweight.  Glaukos Corporation is an ophthalmic medical technology and pharmaceutical compa

Glaukos (GKOS) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

The stock price of Glaukos Corp (NYSE: GKOS) fell 21.41% yesterday. This is why it happened.

Proposed rates from CMS for fiscal 2022 weren't what investors expected.

Centers for Medicare and Medicaid Services (CMS) issued its fiscal 2022 proposed physician fee schedule, which included two combined Category I cataract plus stent procedure codes. The physicians will

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal d

Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

I covered Glaukos twice last year during what I felt like was a temporary setback due to the COVID-19 pandemic. Since that time, Glaukos shares have rallied substantially as those headwinds started to

Investors continue to be optimistic about Glaukos (GKOS) owing to its strategic alliances and a strong iStent product line.

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal d

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal d

Iridex: A Clear Vision For Success

Despite reporting first-quarter loss, Glaukos' (GKOS) results reflect rise in revenues.

Glaukos Corp (GKOS) CEO Tom Burns on Q1 2021 Results - Earnings Call Transcript